$7.45−0.16 (−2.10%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD
Biocryst Pharmaceuticals (BCRX) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
Sources Company filings FilingsHow we compute thisNot investment advice
Business engineGrowing fast: revenue compounds ~53.6%/yr (FY21→FY25), net margin 30.2%, and free cash flow (~$344.9M) tracks net income. Earnings are cash, not paper. Worth your attention in FY25: Share count (+22.0%) and Capex step-up ($2.5M). Both visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)▲94.1%
874.8
FY21→FY25CAGR +53.6%/yr
Net income ($M)—
263.9
FY21→FY25CAGR —
Free cash flow ($M)—
344.9
capex stepped upCAGR —
Diluted EPS—
1.21
FY21→FY25CAGR —
What the receipts whisper · what a headline number hides
Share count
+22.0%
179.1mn → 218.6mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.
Capex step-up
$2.5M
▲120% YoY in FY25, largest jump in this window; watch free-cash-flow conversion.
What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)
30¢ of every revenue dollar becomes profit. The biggest cost lever is operating expenses.
Margin trend · direction beats level Gross Operating Net
Over this window: gross 95.4% → 97.8%. Net margin 30.2% is more than double the sector median.
The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
USD thousands except per-share & ratios
| Line item | TTM † | FY25 | FY24 | FY23 | FY22 | FY21 | YoY | CAGR 21→25 |
|---|---|---|---|---|---|---|---|---|
| Revenue & profitability | ||||||||
Revenue | 961,510.0 | 874,837.0 | 450,712.0 | 331,412.0 | 270,827.0 | 157,170.0 | ▲94.1% | +53.6% |
Cost of revenue | 20,313.0 | 19,075.0 | 12,269.0 | 4,481.0 | 6,408.0 | 7,229.0 | ▲55.5% | +27.5% |
Gross profit | 941,197.0 | 855,762.0 | 438,443.0 | 326,931.0 | 264,419.0 | 149,941.0 | ▲95.2% | +54.6% |
Research & development | 909,129.0 | 166,126.0 | 174,638.0 | 216,566.0 | 253,297.0 | 208,808.0 | ▼4.9% | −5.6% |
Selling, general & admin | 321,486.0 | 348,647.0 | 266,348.0 | 214,074.0 | 159,371.0 | 118,818.0 | ▲30.9% | +30.9% |
Total operating expenses | 1,230,615.0 | 514,773.0 | 440,986.0 | 430,640.0 | 412,854.0 | 327,661.0 | ▲16.7% | +12.0% |
Operating incomefeeds ROC rank | −289,418.0 | 340,989.0 | −2,543.0 | −103,709.0 | −148,435.0 | −177,720.0 | — | — |
Other income, net | −65,314.0 | −73,598.0 | −84,411.0 | −122,520.0 | −95,948.0 | −4,089.0 | — | — |
Pretax income | −354,732.0 | 267,391.0 | −86,954.0 | −226,229.0 | −244,383.0 | −181,809.0 | — | — |
Income tax | 4,924.0 | 3,530.0 | 1,927.0 | 310.0 | 2,733.0 | 2,253.0 | ▲83.2% | +11.9% |
Net incomePiotroski ROA ✓feeds Buffett Quality owner earnings | −359,656.0 | 263,861.0 | −88,881.0 | −226,539.0 | −247,116.0 | −184,062.0 | — | — |
| Per share | ||||||||
Diluted EPSbuyback-sensitive | −1.41 | 1.21 | −0.43 | −1.18 | −1.33 | −1.03 | — | — |
Diluted shares (mn) | 267.62 | 218.58 | 206.70 | 192.20 | 185.91 | 179.12 | ▲5.7% | +5.1% |
| Margins | ||||||||
Gross margin95th pct in Healthcare | 97.9% | 97.8% | 97.3% | 98.6% | 97.6% | 95.4% | ▲0.5pp | +2.4pp |
Operating margin | −30.1% | 39.0% | −0.6% | −31.3% | −54.8% | −113.1% | ▲39.5pp | +152.1pp |
Net margin17th pct in Healthcare | −37.4% | 30.2% | −19.7% | −68.4% | −91.2% | −117.1% | ▲49.9pp | +147.3pp |
† TTM = trailing four quarters through 2026-09-30.
5 more years of statements and CSV export are on Premium, and 12 more on Ultimate.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
These lines feed the tenet checklists: see which gates passTenets →Margins & returns continue as sector-ranked ratiosStatistics →
Annual report filed 2026-02-26 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Statements normalized in our fundamentals DB · Not investment advice.
Common questions
What was Biocryst Pharmaceuticals' revenue last fiscal year?
Biocryst Pharmaceuticals reported revenue of $874.8M in fiscal 2025, up 94.1% from fiscal 2024.
What was Biocryst Pharmaceuticals' net income?
Biocryst Pharmaceuticals reported net income of $263.9M in fiscal 2025, a net margin of 30.2%.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

